Onderneming Asarina Pharma AB (publ) Nasdaq Stockholm
Aandelen
SE0011641794
Biotechnologie & Medisch Onderzoek
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Peter Nordkild
CEO | Chief Executive Officer | 69 | 01-01-16 |
Director of Finance/CFO | 69 | 01-04-17 | |
Public Communications Contact | 63 | 01-01-11 | |
Magnus Brisander
PRN | Corporate Officer/Principal | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Paul de Potocki
CHM | Chairman | 62 | 01-01-18 |
Public Communications Contact | 63 | 01-01-11 | |
Marianne Kock
BRD | Director/Board Member | 69 | 01-01-18 |
Director/Board Member | 50 | 21-01-20 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 22 641 409 | 13 127 611 ( 57,98 %) | 0 | 57,98 % |
Bedrijfsgegevens
Asarina Pharma AB
Karolinska Institutet Science Park Fogdevreten 2
171 65, Solna
+46 8 52 48 44 82
http://www.asarinapharma.com![Adres Asarina Pharma AB (publ)](https://cdn.zonebourse.com/static/address/46336094.png)
Sector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+15,20% | 121 mld. | |
+19,67% | 113 mld. | |
+17,00% | 26,02 mld. | |
-23,86% | 19,39 mld. | |
-19,65% | 15,91 mld. | |
-20,90% | 15,09 mld. | |
-46,14% | 15,06 mld. | |
+63,85% | 14,93 mld. | |
+4,49% | 13,85 mld. |